New OX40 immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Ear, nose & throat, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a locally advanced or metastatic solid tumor that has not responded to or is not eligible for standard treatments
- Your tumor type is one of the following: non-small cell lung cancer, melanoma, head and neck cancer, stomach/esophageal cancer, kidney cancer, bladder cancer, or a tumor with high MSI, high TMB, or MMR deficiency
- You have not previously taken a drug targeting OX40
- You do not have an active autoimmune disease or immune system condition requiring steroids or other immune-suppressing drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OBX-115, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments.
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests two new drugs, HX009 and IN10018, with or without standard chemotherapy, for people with advanced solid tumors that haven't responded to treatment or have no standard options. It aims to see if this combination can help shrink or control the cancer.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.